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Therapeutic Effects of Metformin
on Cancer
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Abstract
Metformin, the first-line antidiabetic drug, has become an attractive candidate
in cancer therapy since retrospective clinical investigations reported that patients
with type 2 diabetes receiving metformin had lower incidence of cancer than those
with other glucose lowering drugs. In line with this, preclinical studies have dem-
onstrated that the antitumor activity of metformin could proceed through several
mechanisms. Thus far, metformin has been used in cancer prevention with reduced
risk as consequence and treatment of various cancers as an adjuvant or neoadjuvant
drug. Thus, existing data support the beneficial effects of metformin on many
types of cancers such as reducing metastasis and mortality and improving patho-
logical responses and survival rates. However, some reports do not support this
and even show adverse effects. The discrepancy may be attributed to expression
levels of its transporters or genetic background. Hence, this chapter briefly
reviews information on the mechanism of metformin action and summarizes
both completed and ongoing clinical trials in an attempt to evaluate the value
of metformin in prevention and treatment of various cancer types.
Keywords: metformin, AMPK, mTORC1, diabetes, lipogenesis, cancer
prevention and therapy, clinical trials
1. Introduction
Metformin is derived from Galega officinalis, a natural herbal medicine. The herb
was first used to relieve polyuria, a symptom of diabetes in ancient Egypt and
medieval Europe [1]. Metformin is a widely used frontline drug for type 2 diabetes
mellitus (T2DM). The major function of metformin is to decrease hepatic gluco-
neogenesis and enhance insulin sensitivity by increasing glucose uptake in muscle
and adipose [2]. In addition to antidiabetes, metformin has proved to be beneficial
to metabolic syndrome and nonalcoholic fatty liver disease [3, 4]. Cancer is charac-
teristic of a metabolic disorder, inasmuch as metabolism is reprogrammed by
switching oxidative phosphorylation into aerobic glycolysis, and thus, many of key
molecules in these two routes are altered in their expression or posttranslational
modification [5]. The incidence of cancer is higher in patients with T2DM than
those without diabetes, indicating that diabetes is a risk factor of cancer [6]. Since
Evan et al. reported in 2005 lower cancer incidence in patients with T2DM taking
metformin than those with other antidiabetic drugs, great efforts have been made to
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elucidate the antitumor activity of metformin [7]. A considerable number of pre-
clinical and clinical investigations support the beneficial effects of metformin on
both prevention and treatment of various cancers. At the same time, some of
mechanisms underlying metformin action on cancer cells have been unraveled,
although much of them is still incomplete. Thus far, more than 300 clinical trials
using metformin as a single or adjuvant agent in combination with other chemo-
therapies have been initiated in the treatment of various types of cancer in the
world (www.clinicaltrials.gov).
2. Targets of metformin
Many functions of metformin are mediated by adenosine monophosphate-
activated protein kinase (AMPK). Metformin at high doses leads to elevation of
AMP, which binds to and allosterically activates AMPK, while at low doses, it
engages lysosomes in the absence of AMP [8, 9]. The upstream kinases that phos-
phorylate AMPK α subunits at Thr172 include liver kinase B1 (LKB1), calmodulin-
dependent kinase beta, and TGF-β-activated protein kinase [10–12].
AMPK plays important roles in regulating lipid and protein metabolisms by
phosphorylating a series of target proteins. Thus, LKB1-AMPK pathway is critically
important for metabolic adaption under stress condition, which aims to protect cells
in the beginning [13]. However, persistent activation of AMPK by metformin can
also cause cytostatic and even cytotoxic effects. Mounting evidence shows that
metabolic syndrome and diabetes increase the risk of cancer, and correction of
metabolic abnormalities alleviates cancer burdens and improves survival [14–16].
Drugs that target AMPK or downstream molecules are research focus nowadays for
cancer prevention and treatment. Some of pathways downstream of AMPK essen-
tial for tumorigenesis and cancer progression are depicted in Figure 1.
PI3K-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) path-
way is well received as the target of AMPK. Mammalian target of rapamycin com-
plex 1 (mTORC1) consists of mTOR, regulatory-associated protein of mTOR
(Raptor), mammalian lethal with SEC13 protein 8, proline-rich AKT substrate
40 kDa, and DEP domain-containing mTOR-interacting protein [17]. Tuberous
sclerosis complex 2 (TSC2) is a GTPase-activating protein that forms a complex
with TSC1 to stimulate GTPase activity of Ras homolog enriched in brain (Rheb)
and thus inhibits mammalian target of rapamycin complex 1 (mTORC1) activation.
TSC2 is subjected to inhibition by AKT and activation by AMPK via phosphoryla-
tion at different sites. In addition, AMPK phosphorylates and inhibits Raptor, a
scaffold of mTORC1. A plethora of cellular events, such as protein translation,
lipogenesis, cell cycle progression, and autophagy, are regulated by the activated
mTOR pathway, which are counteracted by AMPK [18]. Thus, control of mTORC1
activity is crucial for prevention and treatment of cancer.
Cancer cells always require large amount of building blocks for dividing pro-
genitor cells. Thus, synthesis of fatty acid and cholesterol is very active [19].
Acutely, AMPK inhibits acetyl CoA carboxylase (ACC) and HMG-CoA reductase
(HMGCR), which are rate-limiting enzymes for de novo synthesis of fatty acid and
cholesterol, respectively [20]. In addition, AMPK activates malonyl-CoA decarbox-
ylase (MAD) that converts malonyl-CoA to acetyl CoA. As cytosolic malonyl-CoA
decreases, fatty acid synthesis is attenuated [17, 21]. AMPK also influences de novo
synthesis of glycerolipid by inhibiting the rate-limiting enzyme glycerol phosphate
acyltransferase (PAT) [17, 22]. Chronically, AMPK phosphorylates sterol regulatory
element-binding protein-1c (SREBP-1c) and its related protein carbohydrate-
response-element-binding protein (ChREBP), restricting the nuclear localization of
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these transcription factors, so as to inhibit transcription of target genes for lipogen-
esis, including those encoding ACC and fatty acid synthase (FASN) [23].
3. Clinical investigations
Decreases from 20 to 94% in cancer risk among patients with T2DM after the
use of metformin have been reported since 2005 [24]. A large population study
conducted by Taiwan National Health Insurance Data Survey evaluated 16,602
individuals treated with metformin or other antidiabetic drug between 2000 and
2007 and concluded a 88% reduction in the risk of various cancer types after
metformin treatment [25, 26]. In line with this, numerous investigations provided
supporting data that metformin reduced incidence of various cancers. For example,
DeCenci et al. have found a 30% decrease in cancer incidence in patients with
T2DM treated with metformin compared to those with other drugs [27, 28]. Currie
et al. conducted a large cohort study with around 60,000 patients from the UK
database and revealed that metformin alone decreased the incidence of colorectal
and pancreatic cancer compared with insulin and sulfonylureas monotherapy after
the adjustment of confound bias, but this was not seen in breast cancer (BC) and
prostate cancer [29]. It is noteworthy that metformin plus insulin could alleviate the
progression of cancer [hazard ratio (HR) = 0.54, 95% confidence interval (CI) 0.43–
0.66] [29]. With respect to mortality, ZODIAC trial with a 10-year follow up has
indicated a lower death rate of cancer among metformin users with T2DM [30].
According to Noto et al. meta-analysis, diabetic patients taking metformin showed
significant reduction of incidence of multiple types of cancer [risk ratio (RR) = 0.67,
0.53–0.85], including colorectal cancer (CRC) (RR = 0.68, 0.53–0.88) and cancer
Figure 1.
AMPK activation and its biological functions. AMPK is activated by increased AMP:ATP ratio induced by
metabolic stress and metformin. In addition, metformin can activate AMPK through lysosomal pathway, where
v-ATPase-regulator-AXIN/LKB1-AMPK complex is formed. After activation, AMPK acts on multiple
molecules/pathways, including inhibition of mTORC1, lipogenesis and IGF-1 expression, and activation of p53
and FOXO3a [17, 22, 87–89]. As such, AMPK regulates cell proliferation, autophagy, and apoptosis of
cancer cells.
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mortality (RR = 0.66, 95% CI = 0.49–0.88) [31]. A study of Bowker et al. reported
that metformin decreased cancer mortality in T2DM, as compared with insulin and/
or sulfonylurea groups [32]. After 1-year observation, the cancer death rate of
metformin, insulin, and sulfonylurea users is 3.5, 8.8, and 4.9 per 1000 patients,
respectively.
Regarding tumor types, dosage of metformin, study setting, and period of
intervention associated with the treatment outcomes, examples are listed in
Table 1.
Cancer type Intervention Outcome
Breast cancer
Bodmer et al.
[39]
Metformin or other
antidiabetic drugs
Diabetic patients treated with metformin ≧ 5 years had
a lower incidence of cancer, compared with nonusers
or short-term (<5 years treatment) metformin users
Jiralerspong
et al. [45]
Metformin + chemotherapy The pCR rate in 68 diabetic patients treated with
metformin, 87 diabetic patients without metformin,
and 2374 nondiabetic patients was 24, 8, and 16%
(P = 0.02)
Niraula et al.
[46]
Metformin Reduction of cancer cell proliferation (Ki67) by 3%
(P = 0.016) and increases in apoptosis by 0.49%
(P = 0.004) was compared between pre- and post-
surgery, despite minor change of fasting insulin level
Hou et al. [51] Metformin + chemotherapy 1013 BC patients with diabetes and 4621 BC patients
without diabetes were analyzed. Nondiabetic group
had higher 5-year survival rate than diabetic group (82
vs. 79%, P < 0.001). In diabetic subgroup, metformin-
treated group had significant higher 5-year survival
rates than nonmetformin-treated group (88 vs. 73%,
P< 0.001)
El-Haggar
et al. [42]
Metformin + chemotherapy
or +hormone therapy,
tamoxifen
Non-diabetic women with newly diagnosed BC (68/
129) were prescribed with metformin (860 mg b.i.d.)
along with chemotherapy or hormone therapy
compared to nonmetformin-treated control arm over 6
or 12 months. A 3.27-fold decrease (P = 0.023, 95% CI
1.17–9.06) at the time of developing metastasis and an
increase in average DFS by 2.137 (P = 0.044) in the
metformin-treated group. Also, the levels of IGF-1, the
ratio of IGF-1 to IGFBP-3, insulin, fasting blood
glucose, HOMA-IR index notably decease, while
IGFBP-3 levels significantly increase after using of
metformin
He et al. [53] Metformin or other
antidiabetic drugs
A cohort study evaluated a total of 1983 women with
stage ≧ 2 Her2 positive BC. Among 154/1983 diabetic
patients who had already responded to previous
chemotherapy. Metformin users had prolonged OS
(HR = 0.52, 95% CI 0.28–0.97, P = 0.041) and reduced
cancer-specific mortality of BC (HR = 0.47, 95% CI
0.24–0.90, P = 0.023), compared with nonusers
Colon cancer
Coyle et al.
[33]
Metformin Significant benefit of RFS (n = 623 patients in two
studies), OS (n = 1936 patients in five studies), and
CSS (n = 535 patients in two studies) was observed in
metformin-treated patients from 3094 patients with
early stage CRC in nine studies, compared with that in
nonmetformin using group
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Cancer type Intervention Outcome
Rokkas and
Portincasa
[55]
Metformin A significant decrease in the risk of developing colon
neoplasia [RRs (95% CI) = 0.75 (0.65–0.87), Z =3.95,
P < 0.001], including the reduction of colon cancer
[0.79 (0.69–0.91), Z = 3.34, P < 0.001] and colon
polyps [0.58 (0.42–0.80), Z = 3.30, P < 0.001]
among patients with T2DB after metformin treatment
Garrett et al.
[58]
Metformin or other
antidiabetic drugs
After adjustment of cofound variates, a 30% increase
in OS was demonstrated among 424/4758 patients who
were diagnosed of T2DM and CRC and administrated
to metformin as compared with that in other
antidiabetics users
Higurashi
et al. [59]
Metformin A total of 151 nondiabetic patients with CRC after
polypectomy was randomized to metformin-treated
arm (250 mg daily over 1 year) or placebo control arm
with 1-year endoscopy reports. The incidence of total
polyps and adenomas decreased in metformin-treated
group by 18.5% [RR = 0.67, 95% CI (0.47–0.97),
P = 0.034] and 21% [RR = 0.60, 95% CI (0.39–0.92),
P = 0.16], compared with that in control group
Endometrial cancer
Sivalingam
et al. [60]
Metformin A total of 40 women with atypical endometrial
hyperplasia (AEH) or EC was assigned to receive
metformin 850 mg b.i.d. over average 20 day, or no
treatment before hysterectomy. Ki67 was reduced by
17.2% (95% CI 27.4–7.0, P < 0.002) in metformin-
treated group
Schuler et al.
[61]
Metformin 20 nondiabetic women with EC and obesity
(BMI ≥ 30) were administrated with metformin
850 mg daily for 1–4 weeks before surgery. The levels
of Ki67 and p-S6 were reduced between pretreatment
and postsurgery by 11.75% (P = 0.008) and 51.2%
(P = 0.0002), respectively. Besides, the levels of p-
AMPK (P = 0.00001), p-Akt (P = 0.0002), p-4EBP1
(P = 0.001), and ER (P = 0.0002) also decreased after
surgery
Mitsuhashi
et al. [63]
Metformin + MPA 17 AEH and 19 noninvasive EC patients received
metformin (escalating from 750 to 2250 mg daily)
after complete response treated by MPA and other
drugs. Relapse rate among patients was 10%, and
estimated 3-year RFS rate was 89%
Nevadunsky
et al. [66]
Adjuvant metformin Metformin significantly improved OS (HR = 0.54, 95%
CI 0.30–0.97, P < 0.04) in diabetic patients with
nonendometrioid EC when compared with that in
nonusers with EC
Acute lymphoblastic leukemia
Ramos-
Peñafiel et al.
[67]
Metformin + prednisone A total of 102 nondiabetic patients with ALL was
enrolled, 26 received metformin (850 mg t.i.d.) for
6 days during preinduction stage, and 76 were treated
with traditional chemotherapy without metformin.
The use of metformin prevented therapy failure and
early relapse (P = 0.025) in patients bearing relative to
high levels of ABCB1
Esophageal Cancer
Skinner et al.
[68]
Neoadjunvant
metformin + CRT
Metformin users along with CRT resulted in higher
pCR (34.5%) than nonmetformin cohort (4.8%,
5
Preventive and (Neo)Adjuvant Therapeutic Effects of Metformin on Cancer
DOI: http://dx.doi.org/10.5772/intechopen.91291
3.1 The role of metformin in radiotherapy and chemotherapy
Metformin has been reported to be a useful adjuvant drug to radiotherapy or
chemotherapy for different cancers, especially prostate and colon cancers [33]. The
effects of metformin on overall survival (OS), relapse-free survival (RFS), and
cancer-specific survival (CSS) after concurrent chemotherapy and/or radiotherapy
vary on cancer types.
Cancer type Intervention Outcome
P = 0.01) and nondiabetic patients (19.6%, P = 0.05).
Higher pCR rate was found to be associated with
higher metformin dose (≥1500 mg/d). Post-CRT
maximum SUV decreased significantly in patients
taking metformin (P = 0.05)
Lee et al. [25] Adjuvant metformin Reduction of total CID and incidence of some
gastroenterological cancers including CRC, HCC, and
so on, among which the CID of esophageal cancer
decreased in diabetic groups taking adjuvant
metformin in comparison to non-DM groups.
Metformin dosage giving rise to a significant decrease
in cancer incidence was ≤500 mg/day
Leamm et al.
[69]
Metformin + neoadjuvant
chemo(radio)therapy
No statistically significant difference between
metformin users and nonmetformin users for median
overall survival (43.6 vs. 42.8 months, P = 0.66) or for
median DFS (31.1 vs.47.0 months, P = 0.68)
Prostate cancer
Wright et al.
[70]
Metformin A reduced risk of prostate cancer was showed among
white men at age of 35–74 after the use of metformin,
as reported by a case-control study
Rothermundt
et al. [74]
Metformin A total of 44 men with castration-resistant prostate
cancer was assigned to receive metformin 500 mg b.i.
d. until progression. After initial metformin treatment,
changes in IGF and IGBP3 and improvement of insulin
sensitivity from baseline were observed but without
correlation with progression. At week 4, only four
patients did not have progression (95% CI, 3–22).
Average PFS was 2.8 months (95% CI, 2.8–3.2) and
PSA double time declined in 23 patients but not
significant
Joshua et al.
[75]
Metformin Metformin 500 mg t.i.d. was prescribed to 24 men
with operable prostate cancer before prostatectomy. In
a per patient and per tumor analyses, Ki67 was
reduced by 29.5% (P = 0.0064) and 28.6%
(P = 0.0042) in comparison with the initial biopsy and
postprostatectomy sections
Rieken et al.
[77]
Metformin Metformin users with prostate cancer exhibited a
minor improvement of RFS after prostatectomy
Spratt et al.
[78]
Metformin A retrospective study examined 2901 noninvasive
prostate cancer patients through radiation therapy. In
157 patients treated with metformin, PSA-RFS and
DMFS were improved and the castration-resistant
prostate cancer progression was alleviated
Table 1.
Examples of clinical investigations of metformin used as a neoadjuvant and adjuvant agent in cancer therapy.
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A previous study has shown that metformin increases radiosensitivity of luminal
BC by influencing expression of thioredoxin and intracellular redox homeostasis
[34]. A high level of AMPKα expression correlates with the increased radiosensitiv-
ity and better prognosis. A systemic review and meta-analysis conducted in 2018
summarized the impact of metformin on the efficacy of radiotherapy in 17 studies,
including prostate cancer, head and neck cancer, rectal cancer, lung cancer, esoph-
ageal cancer, and liver cancer [35]. The study compared diabetic patients with
metformin (D + M) and diabetic or nondiabetic cohort without metformin (D M
or N M) after radiotherapy. An improved pathologic complete response (pCR),
2y-OS, and 5y-OS vary in different cancer types when analyzing D + M and D M
groups, supporting that metformin is beneficial to OS of diabetic patients while
distant metastasis-free survival (DMFS) and 5-year OS were not significantly dif-
ferent between D + M and N M groups. With respect to the possible mechanisms
by which metformin enhances radiosensitivity, studies have indicated that p53 and
AMPKα are involved [36, 37]. Despite the increased sensitivity to radiotherapy and
chemotherapy, cumulative side effects and toxicity concur with the use of metfor-
min. For example, a study has shown that combination of metformin with radio-
chemotherapy can lead to less tolerance to cisplatin and radiotherapy and
exacerbate gastrointestinal adverse effects such as grade ≥ 3 nausea/vomiting [38].
3.2 Breast cancer
Several lines of clinical investigations have been conducted to assess the benefi-
cial effects of metformin on BC [39–52]. Two retrospective studies revealed that
long-term use of metformin (>5 years) reduced the risk of BC in T2DM women as
compared with other antidiabetic drugs [39, 40]. However, Currie et al. reported
that metformin use did not affect risk of breast and prostate cancer, but the reduced
risk was found in colon and pancreas cancer [29].
He et al. have shown improvement of disease-free survival (DFS), DMFS, and
OS in diabetic women who well-responded to previous hormone therapy and then
received metformin treatment. The results demonstrated that metformin synergizes
with hormone therapy [53, 54].
Metformin was used as neoadjuvant chemotherapy of BC to improve patholog-
ical conditions prior to surgery [45–48]. The increased pCR in 2529 women with BC
has been demonstrated in metformin-treated diabetic patients, compared to
nonmetformin-treated patients with or without diabetes [45]. Another study by
Niraula et al. evaluated the effect of metformin on serum biomarkers in nondiabetic
BC patients before surgery [46]. The patients were treated with metformin for 2
weeks, and serum biomarkers were assessed. A notably reduction of Ki67 and
elevation of apoptosis were observed in invasive tumor after the use of metformin.
The significant decrease of homeostatic model assessment of insulin resistance (-
HOMA-IR) was also observed, while insulin and leptin displayed a modest change.
However, a study showed that metformin increased phospho-AMPK (p-AMPK)
and decreased p-Akt and Ki67 without induction of apoptosis, suggesting a cyto-
static effect [47].
The long-term use of metformin has been shown to reduce risk of distant
metastasis and mortality of BC patients with type 2 diabetes [49–51]. Furthermore,
metformin use as adjuvant therapy can also improve outcomes of BC in nondiabetic
patients [41, 42, 52]. For example, a single-arm phase II trial enrolled nondiabetic
women with M0 stage BC. After receiving metformin of 500 mg t.i.d. for 6 months,
the result showed that fasting insulin level and HOMA-IR were significantly
reduced. Total cholesterol, low density lipoprotein, and leptin also similarly
declined [52]. Another study focused on the optimal dose of metformin that
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achieves favorable effects on BC by comparing dose between 1500 and 1000 mg
daily [41]. For postmenopausal women with basal testosterone levels≧0.28 ng/mL,
it seemed that metformin of 1500 mg/d was better than 1000 mg/d in reduction of
insulin and testosterone levels, which were associated with cancer incidence and
prognosis. Combination of metformin with other chemotherapy usually generates
better outcomes in nondiabetic BC patients with the higher HOMA-IR (>2.8), and
HOMA-IR can be improved by metformin [42–44, 48].
In summary, studies showing beneficial effects of metformin are more than
those without effects. Metformin as an adjuvant agent can suppress BC at various
doses ranging from 500 to 1500 mg. The outcomes mainly include reduced risk of
BC, decreases in cancer-promoting markers and metastatic events, increases in
apoptotic markers, and improvement of progression-free survival (PFS) and OS.
3.3 Colon cancer
The role of metformin in preventing colon cancer has been documented in the
following studies conducted in both diabetic and nondiabetic patients. A meta-
analysis was carried out in 709,980 individuals with T2DM from 17 studies showing
a significant decrease in the risk of colon neoplasia among metformin-treated
patients compared to those without metformin, with respective reduction for either
cancer or polys [55]. A randomized study enrolled a total of 26 nondiabetic individ-
uals with aberrant crypt foci (ACF) (biomarker of CRC development) and assigned
them to either receive metformin 250 mg daily for 1 month or control group [56].
Significant decreases in the average number of ACF by a 3.67-fold (P = 0.007) and
in proliferating cell nuclear antigen index were discovered in metformin arm. This
indicates that metformin prevents CRC by attenuating cell proliferation and ACF
development.
Metformin has been used as an adjuvant agent in the treatment of CRC. First,
a single-arm study has demonstrated a median PFS of 1.8 months and an OS of
7.9 months in metastatic CRC with combination of metformin (850 mg b.i.d.) and
5-fluorouracil treatment. Surprisingly, the improvement in median survival was
more obvious in obese patients [57]. Second, Coyle et al. have evaluated 3092
patients with early stage of CRC [33]. It was found that the use of metformin
significantly improved RFS (HR = 0.63, 95% CI 0.47–0.85), OS (0.69, 95% CI 0.58–
0.83), and CSS (0.58, 95% CI 0.39–0.86) in patients with T2DM, compared with
other antidiabetic drugs. Likewise, progression of CRC is also inhibited by metfor-
min. A similar study showed prolonged OS in patients with T2DM with CRC
receiving metformin, as compared with nonmetformin users (79.6 vs. 56.9 months,
P = 0.048) [58]. The last randomized trial used metformin (250 mg daily) for a year
in nondiabetic patients with high-risk adenoma recurrence and no colorectal polyps
after polypectomy [59]. The results showed that polyps and adenomas are notice-
ably fewer in the metformin arm than in the control arm. The study also showed
that average HOMA-IR status was significantly reduced in nonrecurrent patients by
metformin, while the value remained stable in recurrent patients, indicating that
insulin resistance is associated with chemoprevention outcome.
3.4 Endometrial cancer
Clinical investigations support that metformin could serve as a potential drug
for protection against endometrial cancer (EC) [60–65]. Several studies have
evaluated the effects of short-term use of metformin as a neoadjuvant therapy
between initial recruitment and hysterectomy surgery in nondiabetic women with
EC [60–62]. The first nonrandomized trial has examined the change of Ki67 and
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shown a remarkable reduction after metformin use at 850 mg b.i.d. for average
20 days [60]. A significant reduction in phospho-4E-binding protein 1 (p-4EFBP1)
downstream of mTOR was also observed by immunohistochemistry, while indirect
serum markers of insulin resistance (fasting glucose, insulin, and HOMA-IR) and
leptin only showed a decrease trend but not significant after adjusting difference.
Another preoperative clinical trial was done in nondiabetic women with body mass
index (BMI) ≧ 30 [61]. After taking metformin 850 mg daily for 1–4 weeks prior to
surgery, Ki67, p-AMPK, p-Akt, phospho-S6 Ribosomal Protein (p-S6), and p-4EBP
were significantly lower in resected specimens than in pretreatment. The reduction
of p-AMPK is inconsistent with purported positive effect of metformin. This study
also showed a decrease in estrogen receptor (ER) but not progesterone receptor.
According to a study evaluating the effect of metformin on EC of diabetic
patients (n = 114) as compared with diabetic (n = 136) and nondiabetic (n = 735)
patients without metformin from 1999 to 2009, metformin-treated group exhibits
prolonged OS than nonusers before and after the adjustment of confound bias [66].
A phase II study has examined the effects of long-term metformin (2250 mg daily
until recurrence) on RFS after a complete response to medroxyprogesterone acetate
(MPA) in 17 individuals with atypical endometrial hyperplasia and 19 with EC [63].
The 3-year estimated RFS was 89%, and the 3-year recurrence rate showed a 4.7-
fold decrease in this study compared with a previous study [64]. In contrast to
short-term treatment, the other randomized factorial study does not have a signif-
icant change in PFS/OS after metformin treatment (1700 mg/d for 16 weeks and
1-year follow up) [65].
3.5 Acute lymphoid leukemia
A single study randomized to assign 102 patients with nondiabetic acute
lymphoid leukemia (ALL) into a group of 26 with metformin at 850 mg t.i.d. for
10 days and the rest to the group without metformin before remission therapy [67].
Metformin displayed a beneficial effect on OS in the patients with high levels of
ABCB1 expression, the gene encoding multidrug resistant protein-1. The failure rate
of therapy was significantly reduced and early relapse after remission prevented
by metformin, as compared with nonusers.
3.6 Oesophagal cancer
Oesophagal cancer is deadly cancer with poor prognosis, and patients usually
do survive or die no longer than 30 months after chemoradiation and surgery [68].
A prospective cohort study by Taiwan National Health Insurance revealed a positive
effect of metformin as an adjunct to standard chemotherapies on the cancer inci-
dence density (CID) of gastroenterological cancers [25]. In this study, a decrease in
total CID including esophageal cancer was found in diabetic groups taking adjuvant
metformin in comparison to nondiabetic groups. Another study reported that met-
formin enhanced the efficacy of radiochemotherapy in patients with T2DM
resulting in superior pCR and low postconcurrent chemoradiation (CRT) maximum
SUV compared to patients with T2DM without metformin and non-DM patients
[68]. Additionally, higher pCR rate was correlated with higher metformin dose
(≥1500 mg/d). However, a report in 2015 demonstrated inconsistent results, in
which no difference in pCR was found between metformin users and
nonmetformin users [69]. Furthermore, it was shown that together with
neoadjunvant chemoradiation, metformin did not improve the median OS or
median DFS in diabetic patients with esophageal cancer.
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3.7 Prostate cancer
The effect of metformin on prostate cancer is ambiguous. Studies of Wright and
Stanford have provided a 44% decrease in the risk of prostate cancer among Cau-
casian men with diabetes [70]. However, investigations by others could not obtain
the same conclusion on the incidence of prostate cancer in diabetic patients treated
with metformin, but the mortality might be reduced [71–73]. A single-arm clinical
trial has revealed a decrease in insulin-like growth factor-1 (IGF-1) and an increase
in insulin-like growth factor-binding protein-3 (IGFBP-3), alongside lowering
prostate-specific antigen (PSA), after giving metformin 500 mg b.i.d. over 12 weeks
to patients with castration-resistant prostate cancer [74]. In a single-arm study on
men with biopsy-proven localized prostate cancer, 22 patients were selected to
receive metformin at 500 mg/d or b.i.d., followed by t.i.d. for 28–84 days preceding
their prostatectomy. The results revealed that Ki67 index was reduced by compar-
ing the initial biopsy with postprostatectomy sections [75]. However, the changes
were not recapitulated by another study, although metformin in the prostate tissue
was detected after a median of 34 days prior to prostatectomy [76]. In a retrospec-
tive study, metformin-treated diabetic individuals gained the improvement of RFS
among 6863 patients after radical prostatectomy [77]. Study of Spratt et al. also
demonstrated the significantly elevated PSA-RFS, DFS, and lower cancer mortality
in localized prostate cancer with metformin treatment compared with that of
nonusers [78].
4. Ongoing clinical trials
Previous studies of metformin use as neoadjuvant or adjuvant therapy for vari-
ous types of cancer provide strong rationale of clinical trials in more vigorous
settings. Thus far, more than 300 clinical trials have initiated in the world despite
some are somehow either terminated or withdrawn. Table 2 lists some of them. For
example, NCT02065687 is a randomized, metformin-placebo, phase II/III study
that enrolls a total of 540 participants and examines the effect of adjuvant metfor-
min together with paclitaxel and carboplatin in treatment of stages III–IV or recur-
rent EC. Patients receive metformin twice a day in a 5-year follow up until disease
progression or undesirable adverse effects appear. According to this trial, prolonged
PFS and OS will be observed after the use of metformin together with other che-
motherapeutic drugs. One of the ongoing phase II trials carrying out in 151
premenopausal BC patients with BMI ≧ 25 kg/m2 evaluates treatment effect with
850 mg metformin b.i.d. vs. placebo for a year, by examining the primary outcome
changes of breast density at time points of 6 and 12 months. This study spanning
from March 7, 2014 to June 30, 2020 also identifies biomarkers associated with
metabolic effects of metformin and attempts to find prediction factors of BC risk
(NCT02028221). Also, a trial (NCT02614339) is undergoing to follow-up 3-year
DFS and 5-year OS in nondiabetic patients with stage II high-risk/III CRC treated
with metformin (1000 mg/day) for 48 months. This study has enrolled 593 partic-
ipants and is still recruiting and expected to complete in July 2021.
The trial of double-blinded 2 2 factorial (aspirinmetformin) design registers
160 patients with stages I–III colon cancer who undertake a completed polypectomy
within recent 24 months (NCT03047837). After randomized allocation, patients
will receive metformin at 850 mg b.i.d. or aspirin at 100 mg daily or two drugs
together vs. placebo over 1 year. Immunohistochemistry for NF-κB, glucose metab-
olism, pS6K, and other biomarker will be compared pre- and postintervention
(ClinicalTrials.gov Identifier: NCT03047837).
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NCT number Status Participants Period Intervention Cancer
type
NCT02581137
https://Clinica
lTrials.gov/
show/
NCT02581137
Active (a) 26, (b)18 years
and older (adult,
older adult),
(c) all sex
June 10,
2016 to not
indicated
Drug: metformin
hydrochloride
Oral cancer
NCT02028221
https://Clinica
lTrials.gov/
show/
NCT02028221
Active (a) 151, (b)
21 years to 54 years
(adult), (c) female
March 7,
2014 to
June 30,
2020
Drug: metformin &
placebo
BC
NCT02431676
https://Clinica
lTrials.gov/
show/
NCT02431676
Active (a) 100, (b)
50 years to 65 years
(adult, older
adult), (c) female
May 1, 2013
to
September
1, 2022
Drug: metformin &
placebo
EC
NCT01697566
https://Clinica
lTrials.gov/
show/
NCT01697566
Active (a) 100, (b)
50 years to 65 years
(adult, older
adult), (c) female
May 1, 2013
to
September
1, 2022
Drug: metformin &
placebo
EC
NCT01797523
https://Clinica
lTrials.gov/
show/
NCT01797523
Active (a) 62, (b) 18 years
and older (adult,
older adult),
(c) all sex
May 1, 2013
to October
1, 2020
Drug: metformin,
letrozole, & everolimus
EC
NCT02065687
https://Clinica
lTrials.gov/
show/
NCT02065687
Active (a) 540, (b)
18 years to older
(adult, older
adult), (c) female
Match 17,
2014 to
Drug: carboplatin,
metformin
hydrochloride,
paclitaxel, & placebo
EC
NCT03047837
https://Clinica
lTrials.gov/sh
ow/
NCT03047837
Recruiting (a) 160, (b)
18 years to 80 years
(adult, older
adult), (c) all sex
March 15,
2017 to
March 15,
2020
Drug: aspirin
(ASA) + metformin
(MET)|Drug: ASA|Drug:
MET|Drug: placebos
Tertiary
prevention
in colon
cancer
NCT01905046
https://Clinica
lTrials.gov/
show/
NCT01905046
Recruiting (a) 128, (b)
25 years to 55 years
(adult), (c) female
August
2013 to
Drug: metformin
hydrochloride &
placebo
BC
NCT02614339
https://Clinica
lTrials.gov/
show/
NCT02614339
Recruiting (a) 593, (b)
20 years to 80 years
(adult, older
adult), (c) all sex
December
2015 to July
2021
Drug: metformin &
placebo
CRC
NCT03378297
https://Clinica
lTrials.gov/
show/
NCT03378297
Recruiting (a) 143, (b)
18 years and older
(adult, older
adult), (c) female
May 4,
2018 to
June 1,
2020
Drug: metformin &
acetylsalicylic acid &
drug: olaparib & drug:
letrozole
Ovarian
cancer
NCT03685409
https://Clinica
lTrials.gov/
show/
NCT03685409
Recruiting (a) 62, (b)20 years
to 70 years (adult,
older adult),
(c) all sex
October 1,
2018 to
September
30, 2020
Drug: metformin
hydrochloride &
placebo
Oral cancer
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5. Cautions to be considered
5.1 Cancer type-specific effects
Whether a cancer type is sensitive to metformin depends on expression level of
OCT1 in the cell membrane. Thus far, majority of previous studies have demon-
strated that metformin exerts beneficial effects on different types of cancer, while
some do not respond. On contrary, in some cases, for example, in glioma and
leukemia cancer cells, metformin reduces cisplatin-induced apoptosis, suggesting
that metformin exerts a protective effect on cytotoxic agents in some cells [79].
Hence, before going to clinical trials, preclinical tests should be undertaken to
ascertain if metformin enhances the inhibitory effect of other drugs. This is feasible
when PDX animal models or organoid culture techniques are available.
5.2 Genetic background of cancer
Responses of cancer cells with and without LKB1 to metformin are different.
Metformin exerts cytostatic effect on cancer cells with wild-type LKB1, while it
causes cytotoxicity in cells lacking LKB1. If metformin is used together with most of
chemotherapeutic drugs that are cytotoxic in cancer containing wild-type LKB1, the
cooperative effects might not be achieved. The reason is that more rapidly dividing
cells are more sensitive to cytotoxic drugs, while cytostatic drugs slow down speed
of cell growth, which might compromise the efficacy of cytotoxic chemotherapy. In
this scenario, it might be a good idea to take metformin and cytotoxic drug alter-
nately. For example, patients take a couple of cycles of cytotoxic chemotherapy and
then have rest for period of time during which metformin is alternately used. The
purpose is to restrain cancer in dormancy and allow the patients to restore healthy
condition. In addition, Birsoy et al. have delineated that the most metformin-
sensitive cells contain mutations of genes responsible for upregulation of mito-
chondrial oxidative phosphorylation, for example, complex I components, or glu-
cose utilization [80]. Thus, these genes may serve as biomarkers for metformin use.
Altogether, these studies point to importance of personalized medicine to deter-
mine the efficacy of metformin in cancer therapy.
5.3 Sensitivity of cancer stem cells
Cancer stem cells (CSCs) are refractory to chemotherapy, leading to the relapse
of cancer. These cells metastasize to distant organs after flowing in circulation,
resulting in poor prognosis. Thus, CSCs have become an important target for anti-
cancer therapies. Hirsch et al. have reported that the CSCs derived from BC are
preferentially sensitive to metformin that is used from 10 to 100 times less dosage
NCT number Status Participants Period Intervention Cancer
type
NCT01864096
https://Clinica
lTrials.gov/
show/
NCT01864096
Recruiting (a) 408, (b)
18 years to 79 years
(adult, older
adult), (c) male
October 1,
2013 to
August 1,
2024
Drug: metformin &
placebo
Prostate
cancer
Table 2.
Summary of ongoing clinical trials approved by FDA.
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than nonstem cancer cells [81]. This finding suggests that metformin could effec-
tively prevent metastasis. It is especially meaningful in the case of surgically
resected cancer when local metastasis in lymph nodes is cytologically tested nega-
tive, but a few CSCs may escape to circulation. At this time, metformin can be used
as preventive measure.
Previous studies have demonstrated that metformin selectively targets CSCs via
regulation of different pathways in various cancer types including breast, pancre-
atic, prostate, and colon cancer [82, 83]. For example, Zhu et al. have shown that
metformin inhibits CD61high/CD49fhigh subpopulation, markers of tumor initiating
cells, by inactivating epidermal growth factor receptor/ErbB2 signaling. Similarly,
CD133+, aldehyde dehydrogenases 1+, and other molecules are inhibited in pancre-
atic and colon cancer through inhibition of the Akt/mTOR pathway [84, 85]. How-
ever, a recent study using head and neck squamous cell carcinoma has shown that
metformin protects CSCs against the cisplatin-induced cell death when combining
these two, which discord with previous studies [86]. Thus, it should be cautious
to ascertain if metformin exerts inhibitory or protective effects on specifically
originated CSCs.
6. Conclusion
Metformin is a cheap and nontoxic first-line antidiabetic medicine. It is an
attractive drug that is being repurposed for multiple usages in treatment of other
diseases in addition to diabetes. Metformin implements its function through AMPK-
dependent and independent mechanisms. Preclinical and retrospective clinical
investigations have inspired clinical trials of metformin use in various cancer ther-
apies. It is a promising drug in neoadjuvant and adjuvant therapies. We hope these
trials will come to end with positive or negative results in the next few years. In
considering genetic heterogeneity of cancer, responses of different cancer types and
subpopulations in the same cancer might be different. Therefore, we still have long
way to go and loads of questions to be addressed.
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